Loading
A phase 3 trial of Cadonilimab in hepatocellular carcinoma, run by Akeso, now recruiting.
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection is a phase 3 interventional study registered as NCT05489289 by Akeso, with 570 participants planned, started 2023-01-05 and due to reach its primary completion in 2026-01-28. Interventions recorded: AK104, placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.